ArticleComprehensiveAnalysisofAlternativeSplicingAcrossTumorsfrom8,705PatientsGraphicalAbstractHighlightsdSystematicanalysisofalternativesplicinglandscapeacross8,705cancerpatientsdSomatictrans-sQTLanalysisidentifiesdriversofglobalsplicingaberrationsdManytumorscontainnumerousneojunctionsnottypicallyfoundinnormalsamplesdNeojunctionscanbeconfirmedbyMSandformaclassofpotentialneoantigensAuthorsAndre´Kahles,Kjong-VanLehmann,NoraC.Toussaint,...,ChrisSander,TheCancerGenomeAtlasResearchNetwork,GunnarR€atschCorrespondencegunnar.ratsch@ratschlab.orgInBriefApan-canceranalysisbyKahlesetal.showsincreasedalternativesplicingeventsintumorsversusnormaltissueandidentifiestrans-actingvariantsassociatedwithalternativesplicingevents.Tumorscontainneojunction-derivedpeptidesabsentinnormalsamples,includingpredictedMHC-Ibindersthatareputativeneoantigens.RNAWXSAlternativeSplicingQuantificationTumorGermlineNormalvs.TumorSomatic(MC3)...CCCGTACCCGTATumor-specificNeojunctionsNeojunctionsoverCancersSomatictrans-sQTL+ERRERWSLLLSYL-NDENDGLYWSGLTTSTMVSTTATNDENDGLEKMHCBindingCPTACMSPredictedNeoepitopesNDENDGLYFERRERWSLLTTSTMVSTS+HLAtype1.90.50.41.31.71.5aca+b2c+a+bPSI=bPSICCCAAAGTEx-FILTER..ERRERWSRK..NDENDGLEK..TTSTMVSKR..ERRERQLLVR....NDENDSYL-..TTSTTATCE.....Kahlesetal.,2018,CancerCell34,211–224August13,2018ª2018TheAuthors.PublishedbyElsevierInc.https://doi.org/10.1016/j.ccell.2018.07.001CancerCellArticleComprehensiveAnalysisofAlternativeSplicingAcrossTumorsfrom8,705PatientsAndre´Kahles,1,2,12,14,15Kjong-VanLehmann,1,2,12,14,15NoraC.Toussaint,3,14MatthiasH€user,1,12,14StefanG.Stark,1,2,12,14TimoSachsenberg,5OliverStegle,4OliverKohlbacher,5,6,7,8,9ChrisSander,10,11TheCancerGenomeAtlasResearchNetwork,andGunnarR€atsch1,2,12,13,14,16,*1ETHZurich,DepartmentofComputerScience,Zurich,Switzerland2MemorialSloanKetteringCancerCenter,ComputationalBiologyDepartment,NewYork,USA3ETHZurich,NEXUSPersonalizedHealthTechnologies,Zurich,Switzerland4EuropeanMolecularBiologyLaboratory,EuropeanBioinformaticsInst...
